ArticleNature communications2024

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.

Chang-Ching Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.